**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application. Please cancel claims 13-14, 26-28, and 38 without prejudice or disclaimer of the subject matter therein. Please amend claims 7, 12, 15-18, 32, and 36, as indicated below:

1-6. (Canceled)

7. (Currently amended) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV), wherein a full length cDNA of JEV is cloned into a BAC vector.

8. (Previously presented) The cDNA clone as set forth in claim 7, wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

9. (Previously presented) The cDNA clone as set forth in claim 8, wherein the promoter is SP6 or T7.

10. (Previously presented) The cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence [[is]] does not exist in the JEV genomic RNA.

11. (Previously presented) The cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence is *XHo* I or *Xba* I.

12. (Currently amended) The cDNA clone as set forth in claim 8, wherein the cDNA clone has ~~is selected from a group consisting of~~ a sequence ~~sequences~~ represented by SEQ. ID. No ~~43 and No 44, and No~~ 45, ~~which all have~~ having SP6 promoter ~~or~~ and ~~a sequence~~ ~~sequences represented by SEQ. ID. No~~ 46 and No 47, and No 48, ~~which all have~~ having T7 promoter.

13-14. (Canceled)

15. (Currently amended) The cDNA clone ~~vector~~ as set forth in claim 7 ~~13~~, wherein the cDNA clone ~~vector~~ is ~~selected from a group consisting of~~ ~~pBAC$^{SP6}$/JVFLI*Xho*I containing the JEV cDNA represented by SEQ. ID. No 43,~~ ~~pBAC$^{SP6}$/JVFLxI*Xho*I containing the JEV cDNA represented by SEQ. ID. No 44,~~ pBAC$^{SP6}$/JVFLxI*Xba*I containing the JEV cDNA represented by SEQ. ID. No 45 or, ~~pBAC$^{T7}$/JVFLI*Xho*I containing the JEV cDNA represented by SEQ. ID. No 46,~~ ~~pBAC$^{T7}$/JVFLxI*Xho*I containing the JEV cDNA represented by SEQ. ID. No 47, and~~ pBAC$^{T7}$/JVFLxI*Xba*I containing the JEV cDNA represented by SEQ. ID. No 48.

16. (Currently amended) The cDNA clone ~~vector according to~~ as set forth in claim 15, wherein the vector is pBAC$^{T7}$/JVFLxI*Xba*I having T7 promoter and deposited under **[[(]]** Accession No : KCTC 10346BP **[[)]]**.

17. (Currently amended) The vector as set forth in claim 15, wherein the vector is pBAC$^{SP6}$/JVFLxl*Xba*I having SP6 promoter and deposited under **[[(]]** Accession No : KCTC 10347BP **[[)]]**.

18. (Currently amended) An infectious JEV RNA transcript ~~synthesized~~ transcribed directly from the cDNA clone of claim 7.

19. (Previously presented) The infectious JEV RNA transcript as set forth in claim 18, wherein virus-unrelated nucleotides at its 3' end are removed.

20. (Previously presented) The infectious JEV RNA transcript as set forth in claim 19, wherein the virus-unrelated nucleotides are removed by treating mung bean nuclease (MBN).

21. (Original) A cell transfected with the JEV RNA transcript of claim 18.

22. (Withdrawn) A synthetic JEV obtained by cultivation of the cell of claim 21.

23. (Withdrawn) A synthetic JEV as set forth in claim 22, wherein a mutation is introduced in the JEV cDNA.

24. (Withdrawn) A method for the expression of heterologous genes using the cDNA clone of claim 8 comprising the following steps:

1) preparing a recombinant JEV cDNA expression vector by inserting heterologous genes into the cDNA clone of claim 8;

2) producing a JEV RNA transcript from the above recombinant JEV cDNA expression vector;

3) preparing a cell transfected with the above JEV RNA transcript; and

4) expressing foreign proteins by culturing the above cell.

25. (Withdrawn) The method as set forth in claim 24, wherein the foreign genes are inserted at the beginning of the JEV 3'NTR of the JEV cDNA.

26 – 28. (Canceled)

29. (Previously presented) The cDNA clone as set forth in claim 8, wherein the JEV genomic RNA consists of a 5' nontranslated region (NTR), a single polypeptide coding region, and a 3' NTR.

30. (Previously presented) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV), comprising:

SEQ. ID. No 45 having SP6 promoter,

wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

31. (Previously presented) A vector, comprising:

a full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV),

wherein the vector is pBAC$^{SP6}$/JVFLx/*Xba*I.

32. (Currently amended) The vector according to claim 31, wherein the vector is pBAC$^{SP6}$/JVFLx/*Xba*I having SP6 promoter and deposited under **[[(]]** Accession No: KCTC 10347BP **[[)]]**.

33. (Previously presented) The vector according to claim 31, wherein the JEV comprises SEQ. ID. No 45.

34. (Previously presented) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV), comprising:

SEQ. ID. No 48 having T7 promoter,

wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

35. (Previously presented) A vector, comprising:

a full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV),

wherein the vector is pBAC$^{T7}$/JVFLx/*Xba*I.

36. (Currently amended) The vector according to claim 35, wherein the vector is pBAC$^{T7}$/JVFLx/*Xba*I having T7 promoter and deposited under **[[(]]** Accession No: KCTC 10346BP **[[)]]**.

37. (Previously presented) The vector according to claim 35, wherein the JEV comprises SEQ. ID. No 48.

38. (Canceled)